INTRODUCTION

Apremilast (Otezla, MS: Otezla 30mg) is an ongoing, multicenter, prospective, 32-week, non-randomized study in real-world clinical dermatology settings in Germany. This study is including physician- and patient-reported outcomes regarding treatment satisfaction and effectiveness of apremilast in patients with moderate to severe plaque psoriasis after switching from fumaric acid esters (FAE).

In this first report of APART, an interim analysis of the real-world benefits of apremilast was presented.

METHODS

Study Design

• Patients aged ≥18 years with moderate to severe plaque psoriasis and no prior treatment with a biologic, FAE, or apremilast were being enrolled (Figure 1).

• In Phase 1, patients initiated FAE and were observed for up to 24 weeks.

• Patients who started apremilast 30 mg BID (APR) during Phase 1 were enrolled in Phase 2 and further observed for up to 32 weeks.

• Indication and inclusion criteria according to apremilast Summary of Product Characteristics.

• Patients who initiated apremilast as part of a clinical trial were not eligible for this study.

• No strict visit schedule was performed. 

• An interim analysis as of July 26, 2018, was performed.

RESULTS (cont’d)

Primary Endpoint

The primary endpoint, mean overall TSQM score at Week 24, was 219.2 compared with 190.1 at APR initiation (P<0.0001).

In patients who switched from FAE to APR, significant improvements in mean overall TSQM score were observed as early as Week 8 and were mostly maintained through Week 32 (P<0.0001 for all time points).

Figure 1. APART Study Design

Figure 2. Patient Populations

Figure 3. Improvements in Overall TSQM Score

Figure 4. Mean TSQM Subscale Scores

Figure 5. Patients Achieving PGA Score of 0 or 1

Figure 6. Patients Achieving PaGA Score of 0 or 1

Figure 7. Patients Achieving ScPGA Score of 0 or 1

Figure 8. Mean Percentage Change From Baseline in Pruritus VAS

Figure 9. Patients Achieving ScPGA Score of 0 or 1

Figure 10. Patients Achieving PaGA Score of 0 or 1

Figure 11. Patients Achieving ScPGA Score of 0 or 1

Figure 12. Patients Achieving PaGA Score of 0 or 1

DISCUSSIONS

The authors acknowledge financial support for this study from Celgene Corporation. The authors received editorial support in the preparation of this poster from Amy Shaberman, PhD, of Peloton Advantage, LLC, an OPEN Health Company, Parsippany, NJ, USA.

The authors report the following potential conflicts of interest: JEF, AM, WC, and DP: Celgene; SKL: Celgene; PEA, MS, and BM: Nothing to disclose.